March 20, 2017

TG Therapeutics, Inc. Announces Preclinical Data Presentation at the 2017 American Association for Cancer Research (AACR) Annual Meeting

NEW YORK, March 20, 2017 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ:TGTX), today announced that preclinical data for the Company's anti-PD-L1 monoclonal antibody, has been selected for presentation at the upcoming American Association for Cancer Research (AACR) annual meeting, to be held April 1-5, 2017, at the Walter E. Washington Convention Center in Washington, D.C.

The presentation details are as follows:

Title: Preclinical characterization of a novel fully human IgG1 anti-PD-L1 mAb CK-301 

  • Abstract Number: 4606
  • Date and Time: Tuesday, April 4, 2017, 1:00 PM - 5:00 PM ET
  • Session: Immunoconjugates and Antibodies
  • Location: Halls A-C, Poster Section 26
  • Poster Number: 21

A copy of the above referenced abstract can be viewed online through the AACR meeting website at www.aacr.org. Following the presentation, the data presented will be available on the Publications page of the Company's website at www.tgtherapeutics.com.

ABOUT TG THERAPEUTICS, INC.

TG Therapeutics is a biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Currently, the company is developing two therapies targeting hematological malignancies and autoimmune diseases. TG-1101 (ublituximab) is a novel, glycoengineered monoclonal antibody that targets a specific and unique epitope on the CD20 antigen found on mature B-lymphocytes. TG Therapeutics is also developing TGR-1202, an orally available PI3K delta inhibitor. The delta isoform of PI3K is strongly expressed in cells of hematopoietic origin and is believed to be important in the proliferation and survival of B‐lymphocytes. Both TG-1101 and TGR-1202 are in clinical development for patients with hematologic malignancies, with TG-1101 also in clinical development for autoimmune disorders. The Company also has preclinical programs to develop IRAK4 inhibitors, BET inhibitors, and anti-PD-L1 and anti-GITR antibodies. TG Therapeutics is headquartered in New York City.

Cautionary Statement

Some of the statements included in this press release, particularly those anticipating future clinical trials, timing of clinical trials for anti-PD-L1 antibodies and business prospects and potential uses for anti-PD-L1 antibodies may be forward-looking statements that involve a number of risks and uncertainties.  For those statements, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. Among the factors that could cause our actual results to differ materially are the following: our ability to identify anti-PD-L1 antibodies suitable for clinical development, our ability to successfully and cost-effectively complete preclinical and clinical trials for anti-PD-L1 antibodies; the risk that the data (both safety and efficacy) from future clinical trials will not coincide with the data analyses from prior preclinical and clinical trials; and other risk factors identified from time to time in our reports filed with the Securities and Exchange Commission.  Any forward-looking statements set forth in this press release speak only as of the date of this press release. We do not undertake to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof. This press release and prior releases are available at www.tgtherapeutics.com. The information found on our website is not incorporated by reference into this press release and is included for reference purposes only.

TGTX - G

CONTACT:

Jenna Bosco

Vice President, Investor Relations

TG Therapeutics, Inc.

Telephone: 212.554.4351

Email: ir@tgtxinc.com

Primary Logo

Source: TG Therapeutics, Inc.

News Provided by Acquire Media


Close window | Back to top

Copyright 2017 TG Therapeutics, Inc.